4 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 4 of 4 clinical reviews.
Deep-dive into post-trial follow-up from the LEADER cardiovascular outcomes trial of liraglutide in type 2 diabetes, covering durability of MACE reduction, late safety signals, and long-term clinical implications.
A detailed breakdown of the LEADER trial's primary MACE endpoint, secondary outcomes, time-course analysis, and subgroup responses for liraglutide in type 2 diabetes with high cardiovascular risk.
A detailed breakdown of the LEADER trial's pre-specified and post-hoc subgroup analyses, examining how liraglutide's cardiovascular benefit varied by age, sex, BMI, baseline biomarkers, and race/ethnicity in patients with type 2 diabetes.
Health-economic analyses from the LEADER trial examined whether liraglutide's 13% MACE reduction in high-risk type 2 diabetes justifies its cost per QALY gained, with implications for payer coverage and patient decision-making.